PARP inhibitor shuts down the global translation of thyroid cancer through promoting Pol II binding to DIMT1 pause

Thyroid cancer has become the most frequent endocrine-related malignancy. Currently, a mounting body of evidences support the clinical strategies for extending the benefit of PARP inhibitors beyond BRCA-mutant cancers. However, the functions and molecular mechanisms of PARP inhibitors in thyroid can...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Xiukun, Tian, Mengran, Ning, Junya, Wang, Zhongyu, Guo, Fengli, Zhang, Wei, Hu, Linfei, Wei, Songfeng, Hu, Chuanxiang, Yun, Xinwei, Zhao, Jingzhu, Dong, Qiman, Ruan, Xianhui, Li, Dapeng, Gao, Ming, Zheng, Xiangqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411462/
https://www.ncbi.nlm.nih.gov/pubmed/37564214
http://dx.doi.org/10.7150/ijbs.81895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411462/
https://www.ncbi.nlm.nih.gov/pubmed/37564214
http://dx.doi.org/10.7150/ijbs.81895

Ejemplares similares